Simulations Plus (FRA:SD3) EPS without NRI: €0.78 (TTM As of Feb. 2026)


FRA:SD3 Simulations Plus Inc FRA:SD3
67 GF Score
Price €15.80
GF Value €32.93
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Simulations Plus EPS without NRI?

Simulations Plus FRA:SD3 67 EPS without NRI is €0.78 as of Feb. 2026. GuruFocus rates FRA:SD3 with a GF Score™ of 67/100 and a GF Value™ of €32.93 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 511 Healthcare Providers & Services companies, Simulations Plus ranks worse than 82.78% on this metric.

Simulations Plus's earnings per share without non-recurring items for the three months ended in Feb. 2026 was €0.30. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Feb. 2026 was €0.78.

During the past 12 months, Simulations Plus's average earnings per share (NRI) Growth Rate was 26.80% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was -18.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -4.90% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Simulations Plus's EPS without NRI or its related term are showing as below:

FRA:SD3' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -39.1   Med: 15.7   Max: 78.7
Current: -18.6

During the past 13 years, Simulations Plus's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 78.70% per year. The lowest was -39.10% per year. And the median was 15.70% per year.

FRA:SD3's 3-Year EPS without NRI Growth Rate is ranked worse than
82.78% of 511 companies
in the Healthcare Providers & Services industry
Industry Median: 11.3 vs FRA:SD3: -18.60

Simulations Plus's EPS (Diluted) for the three months ended in Feb. 2026 was €0.19. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 was €-2.79.

Simulations Plus's EPS (Basic) for the three months ended in Feb. 2026 was €0.19. Its EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2026 was €-2.79.


Simulations Plus  (FRA:SD3) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Simulations Plus EPS without NRI Related Terms


Simulations Plus EPS without NRI Historical Data

* Premium members only.

The historical data trend for Simulations Plus's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simulations Plus EPS without NRI Chart

Simulations Plus Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.41 0.61 0.61 0.48 0.29

Simulations Plus Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.40 -0.03 0.11 0.30

FRA:SD3 vs TBRG, CARL, NRC: EPS without NRI Comparison

For the Health Information Services subindustry, Simulations Plus's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Simulations Plus PE Ratio without NRI vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Simulations Plus's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Simulations Plus's PE Ratio without NRI falls into.


FRA:SD3
67GF Score
Simulations Plus Inc FRA:SD3
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Simulations Plus EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €0.78 mean?
Simulations Plus (FRA:SD3) has a EPS without NRI of €0.78 as of Feb. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Simulations Plus and its competitors. According to the industry distribution chart, Simulations Plus ranks #423 out of 511 companies in the Healthcare Providers & Services industry, placing it in the top 82.8%.
Is Simulations Plus' EPS without NRI too high?
Simulations Plus' current EPS without NRI is €0.78. Based on the distribution chart, Simulations Plus ranks #423 out of 511 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Simulations Plus has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Simulations Plus' EPS without NRI compare to TBRG and CARL?
According to the Healthcare Providers & Services industry distribution chart, Simulations Plus ranks #423 out of 511 companies for EPS without NRI. This places Simulations Plus in the lower half of its industry. The industry median EPS without NRI is 11.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Healthcare Providers & Services company?
The median EPS without NRI among Healthcare Providers & Services companies is 11.30, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Simulations Plus and its competitors. For the Healthcare Providers & Services industry, the median EPS without NRI is 11.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simulations Plus's current EPS without NRI is €0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simulations Plus stock overvalued right now?
Based on GuruFocus' analysis, Simulations Plus (FRA:SD3) is currently considered Significantly Undervalued. The stock's GF Value™ is €32.93, compared to a current price of €15.80 — trading 52% below its estimated fair value. The current EPS without NRI is €0.78. Simulations Plus' overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Simulations Plus (FRA:SD3), the current EPS without NRI is €0.78 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Simulations Plus (FRA:SD3) Overvalued in 2026?

Based on GuruFocus' analysis, Simulations Plus stock appears to be undervalued. The current stock price of €15.80 is trading 52% below its estimated GF Value™ of €32.93. GuruFocus considers Simulations Plus to be Significantly Undervalued.

Key valuation signals for FRA:SD3:

  • EPS without NRI: €0.78
  • GF Value™: €32.93 vs. price of €15.80 (52% below fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the FRA:SD3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Simulations Plus Business Description

Other Exchanges SLP:USA
Address 800 Park Offices Drive, Suite 401, Research Triangle Park, Lancaster, NC, USA, 27709
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
67GF Score

Get the complete analysis for FRA:SD3

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.80
Price
€32.93
GF Value